# PAS-004

Source: https://onco.cc/drugs/pas-004/  
OnCo record `pas-004` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PAS-004 is an experimental small molecule from Pasithea Therapeutics, in phase 1 trials for MAPK pathway-driven advanced solid tumours and NF1-associated plexiform neurofibromas.

## Summary

PAS-004 is a small molecule (oral, macrocyclic) from Pasithea Therapeutics. An oral small-molecule allosteric inhibitor of MEK1 and MEK2 with a macrocyclic structure designed to improve metabolic stability and its pharmacokinetic profile. Its furthest stage is phase 1, for MAPK pathway-driven advanced solid tumours (RAS, NF1 or RAF mutations) and NF1-associated plexiform neurofibromas. ClinicalTrials.gov registers it in 2 studies linked below. Two phase 1 trials recruiting: NCT06299839 (advanced solid tumours with RAS, NF1 or RAF mutations) and NCT06961565 (adults with NF1 plexiform neurofibromas). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: PAS-004
- Modality: Small molecule (oral, macrocyclic)
- Mechanism: An oral small-molecule allosteric inhibitor of MEK1 and MEK2 with a macrocyclic structure designed to improve metabolic stability and its pharmacokinetic profile.

## Sources

- Pasithea Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1841330/000121390026036434/ea0275535-10k_pasithea.htm
- Pasithea Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1841330/000121390026036434/ea0275535-10k_pasithea.htm
- Pasithea Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06299839
- ClinicalTrials.gov: trials of PAS-004: https://clinicaltrials.gov/search?intr=PAS-004

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [MEK1/2](https://onco.cc/targets/mek/)
- companies: [Pasithea Therapeutics](https://onco.cc/companies/pasithea-therapeutics/)
- trials: [PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas](https://onco.cc/trials/nct06961565/), [PAS-004 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06299839/)

---
JSON: https://onco.cc/api/v1/entities/pas-004.json